Evoke Pharma, Inc. (NASDAQ:EVOK) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Separately, FBR & Co reaffirmed a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a report on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $7.25.

Shares of Evoke Pharma (EVOK) traded down 1.59% during mid-day trading on Thursday, reaching $2.48. 85,030 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $2.55 and its 200-day moving average price is $2.73. The stock’s market cap is $38.16 million. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Monday, May 15th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter in the previous year, the company posted ($0.45) EPS. Equities research analysts forecast that Evoke Pharma will post ($0.84) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Evoke Pharma, Inc. (EVOK) Upgraded at ValuEngine” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/20/evoke-pharma-inc-evok-upgraded-at-valuengine.html.

A hedge fund recently bought a new stake in Evoke Pharma stock. Sphera Funds Management LTD. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 500,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,550,000. Sphera Funds Management LTD. owned about 4.06% of Evoke Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.70% of the company’s stock.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.